LYNX CAPITAL GROUP LTD /ADV’s Novo Nordisk NVO Stock Holding History

LYNX CAPITAL GROUP LTD /ADV’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.55M	Buy	+15,012	New	+$1.48M	1.13%	41

Other funds holding NVO

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

LYNX CAPITAL GROUP LTD /ADV's NVO Position: Q4 2023 in Review

LYNX CAPITAL GROUP LTD /ADV opened a new position in Novo Nordisk (NVO) in Q4 2023: 15,012 shares worth $1.55M. The stake represents 1.13% of the portfolio and ranks #41 among its holdings.

1,513 funds tracked by Wall St. Rank hold NVO as of Q4 2023.

LYNX CAPITAL GROUP LTD /ADV held 15,012 shares of Novo Nordisk worth $1.55M as of Q4 2023.
Novo Nordisk was a new LYNX CAPITAL GROUP LTD /ADV position in Q4 2023.
Novo Nordisk made up 1.13% of LYNX CAPITAL GROUP LTD /ADV's portfolio in Q4 2023, its #41 holding.
1,513 funds tracked by Wall St. Rank held Novo Nordisk as of Q4 2023.

Based on LYNX CAPITAL GROUP LTD /ADV's 13F filing for Q4 2023, filed 7 Aug 2026.